Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis
Description
The presentation highlights two complex cases of autoimmune connective tissue diseases in adults, focusing on their diagnosis and treatment pathways. The first case involves a 19-year-old female who presents with severe lower extremity edema and painful, ulcerative plaques, initially misdiagnosed as SWEET syndrome before confirming through genetic testing that she had A1 antitrypsin deficiency (specifically the severe ZZ genotype). Despite failing initial treatments, she showed remarkable improvement after starting enzyme replacement therapy. The presentation explains how A1 antitrypsin deficiency can present with skin manifestations like panniculitis, stressing that dermatologists should be aware of such atypical presentations which may occur prior to lung or liver symptoms. The second case discusses a woman in her 50s diagnosed with generalized morphia after presenting with expanding rashes. Despite aggressive treatments including steroids, immunosuppressants, and rituximab, her condition persisted, leading to the decision to try tocilizumab, an IL-6 receptor blocker. She exhibited significant improvement in both skin lesions and functionality after treatment with tocilizumab. The presenter concludes by indicating that tocilizumab may be a viable option for refractory cases of morphia.
View moreConclusions
- Alpha-1 antitrypsin deficiency can lead to severe cutaneous manifestations like panniculitis, which may go undiagnosed due to the absence of pulmonary or liver disease.
- Diagnosis of alpha-1 antitrypsin deficiency-associated panniculitis is often established later in life, often at age 36, compared to the median age of 49 for the disease itself.
- Dermatologists should maintain a high index of suspicion for alpha-1 antitrypsin deficiency in patients presenting with panniculitis even without classic symptoms of lung or liver disease.
- The use of enzyme replacement therapy for alpha-1 antitrypsin deficiency has shown remarkable improvement in skin lesions associated with the condition.
- Dapsone may provide a partial response in some cases of alpha-1 antitrypsin deficiency-associated panniculitis, but enzyme replacement therapy is generally the more effective treatment.
- Generalized morphea may require aggressive treatment strategies including high-dose corticosteroids and immunosuppressive therapy when it is severe or progressive.
- Tocilizumab has been identified as a promising treatment option for refractory cases of morphea, leading to improved symptoms and functionality.
- Franciosi AN, Ralph J, et al. J Am Acad Dermatol. 87(4):825-832
- Dinesh Khanna, Celia J F Lin, Daniel E Furst, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
- Zhang A, Nocton J, Chiu Y. A Case of Pansclerotic Morphea Treated With Tocilizumab. JAMADermatol. 2019;389. doi:10.1001/jamadermatol.2018.5040
- Osminina M, Geppe N, Afonina E. Scleroderma "en coup de sabre" With Epilepsy and Uveitis Successfully Treated With Tocilizumab.
- Ventéjou S, Schwieger-Briel A, Nicolai R, Christen-Zaech S, Morren M-A. Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts.